Shanghai Kehua Bio-Engineering Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.01%

Shanghai Kehua Bio-Engineering Co Ltd (002022) has an Asset Resilience Ratio of 0.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Shanghai Kehua Bio-Engineering Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥299.62K
≈ $43.84K USD Cash + Short-term Investments

Total Assets

CN¥5.17 Billion
≈ $756.56 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2024)

This chart shows how Shanghai Kehua Bio-Engineering Co Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Shanghai Kehua Bio-Engineering Co Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Kehua Bio-Engineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Kehua Bio-Engineering Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥299.62K 0.01%
Total Liquid Assets CN¥299.62K 0.01%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Kehua Bio-Engineering Co Ltd maintains only 0.01% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Kehua Bio-Engineering Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Kehua Bio-Engineering Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Sino Medical Sciences Technology In
SHG:688108
Medical Devices 0.66%
Polynovo Ltd
AU:PNV
Medical Devices 5.46%
Beijing Succeeder Technology Inc
SHG:688338
Medical Devices 28.66%
Tellgen Corp
SHE:300642
Medical Devices 8.60%
Respiri Ltd
AU:RSH
Medical Devices 0.46%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.39%
Duearity AB
ST:DEAR
Medical Devices 145.62%

Annual Asset Resilience Ratio for Shanghai Kehua Bio-Engineering Co Ltd (2002–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Kehua Bio-Engineering Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.01% CN¥293.59K
≈ $42.96K
CN¥5.24 Billion
≈ $766.21 Million
-4.65pp
2023-12-31 4.65% CN¥316.77 Million
≈ $46.35 Million
CN¥6.81 Billion
≈ $996.19 Million
+4.63pp
2018-12-31 0.03% CN¥962.53K
≈ $140.85K
CN¥3.50 Billion
≈ $512.71 Million
+0.01pp
2010-12-31 0.02% CN¥234.08K
≈ $34.25K
CN¥1.09 Billion
≈ $159.05 Million
-0.02pp
2009-12-31 0.04% CN¥363.28K
≈ $53.16K
CN¥925.84 Million
≈ $135.48 Million
-0.28pp
2006-12-31 0.32% CN¥1.56 Million
≈ $228.10K
CN¥484.49 Million
≈ $70.90 Million
-4.11pp
2002-12-31 4.43% CN¥10.00 Million
≈ $1.46 Million
CN¥225.50 Million
≈ $33.00 Million
--
pp = percentage points

About Shanghai Kehua Bio-Engineering Co Ltd

SHE:002022 China Medical Devices
Market Cap
$449.34 Million
CN¥3.07 Billion CNY
Market Cap Rank
#13108 Global
#4119 in China
Share Price
CN¥5.97
Change (1 day)
+0.67%
52-Week Range
CN¥5.42 - CN¥8.06
All Time High
CN¥29.42
About

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more